Browsing by title

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.

Ott, PA; Bang, Y-J; Berton-Rigaud, D; Elez, E; Pishvaian, MJ; Rugo, HS; Puzanov, I; Mehnert, JM; Aung, KL; Lopez, J; Carrigan, M; Saraf, S; Chen, M; Soria, J-C (2017-08)

Purpose The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to evaluate the safety and efficacy of pembrolizumab, an anti-programmed death 1 monoclonal antibody, in patients with programmed death ligand ...

Safety and bio-effects of ultrasound contrast agents.

ter Haar, G (2009-08)

The use of gas-filled microbubbles as ultrasound contrast agents raises potential safety concerns for diagnostic ultrasound imaging. A number of biological effects have been seen in experimental systems, including the ...

Safety and Efficacy of Atezolizumab in Under Studied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.

Merseburger, AS; Castellano, D; Powles, T; Loriot, Y; Retz, M; Voortman, J; Huddart, RA; Gedye, C; Van Der Heijden, MS; Gurney, H; Ong, M; de Ducla, S; Pavlova, J; Fear, S; Sternberg, CN (2021-04-09)

<h4>Purpose</h4>Atezolizumab is an established treatment option for pretreated urothelial carcinoma, demonstrating efficacy in phase II/III trials. The SAUL study enrolled a broader patient population to determine safety ...

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.

Cesne, AL; Bauer, S; Demetri, GD; Han, G; Dezzani, L; Ahmad, Q; Blay, J-Y; Judson, I; Schöffski, P; Aglietta, M; Hohenberger, P; Gelderblom, H (2019-08-13)

<h4>Background</h4>PALETTE is a phase 3 trial that demonstrated single-agent activity of pazopanib in advanced soft tissue sarcomas (aSTS). We performed retrospective subgroup analyses to explore potential relationships ...

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.

Dimopoulos, MA; Palumbo, A; Corradini, P; Cavo, M; Delforge, M; Di Raimondo, F; Weisel, KC; Oriol, A; Hansson, M; Vacca, A; Blanchard, MJ; Goldschmidt, H; Doyen, C; Kaiser, M; Petrini, M; Anttila, P; Cafro, AM; Raymakers, R; San-Miguel, J; de Arriba, F; Knop, S; Röllig, C; Ocio, EM; Morgan, G; Miller, N; Simcock, M; Peluso, T; Herring, J; Sternas, L; Zaki, MH; Moreau, P (2016-07)

Patients with relapsed and/or refractory multiple myeloma (RRMM) have poor prognosis. The STRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest cohort to date of patients ...

The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.

Wilson, JM; Parker, C (2016-09)

<h4>Introduction</h4>A number of drugs have been shown to extend life expectancy in castration-resistant prostate cancer (CRPC). Skeletal related events (SREs) secondary to bone metastases cause significant morbidity for ...

Safety and efficacy of T-DM1 in 128 patients with advanced HER2+breast cancer: The Royal Marsden experience

Battisti, NML; Lee, KA; Shepherd, S; Rogerson, F; Mohammed, K; Allen, M; Ring, A (OXFORD UNIV PRESS, 2019-10-01)

Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience.

Battisti, NML; Rogerson, F; Lee, K; Shepherd, S; Mohammed, K; Turner, N; McGrath, S; Okines, A; Parton, M; Johnston, S; Allen, M; Ring, A (2020-01)

BACKGROUND:Ado-trastuzumab emtansine (T-DM1) is standard of care for patients with advanced HER2+ breast cancer who relapse within 6 months of adjuvant trastuzumab or progress on first-line anti-HER2 therapy. We evaluated ...

Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas.

Pierce, DB; Johnson, GE; Monroe, E; Loggers, ET; Jones, RL; Pollack, SM; Padia, SA (2018-01)

OBJECTIVE:The outcome for patients with unresectable hepatic sarcoma is poor with a median survival period of 12-16 months. The purpose of this study was to evaluate liver-directed transcatheter therapies for the treatment ...

Safety and Feasibility of Surgery for Oropharyngeal Cancers During the SARS-CoV-2-Pandemic.

Gorphe, P; Grandbastien, B; Dietz, A; Duvvuri, U; Ferris, RL; Golusinski, W; Holsinger, FC; Hosal, S; Lawson, G; Mehanna, H; Paleri, V; Shaw, R; Succo, G; Leemans, CR; Simon, C

Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study.

Vasiliadou, I; Breik, O; Baker, H; Leslie, I; Sim, VR; Hegarty, G; Michaelidou, A; Nathan, K; Hartley, A; Good, J; Sanghera, P; Fong, C; Urbano, TG; Lei, M; Petkar, I; Ferreira, MR; Nutting, C; Wong, KH; Newbold, K; Harrington, K; Bhide, S; Kong, A (2021-03-19)

Nivolumab is an anti-PD-1 monoclonal antibody currently used as immunotherapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of disease progression after platinum-based ...

Safety of intrauterine devices in MRI.

Bussmann, S; Luechinger, R; Froehlich, JM; von Weymarn, C; Reischauer, C; Koh, DM; Gutzeit, A (2018-01)

<h4>Objectives</h4>The paucity of safety information on intrauterine devices (IUD) for magnetic resonance imaging (MRI) examinations is clinically relevant. The aim of this study is to evaluate the MRI safety of clinically ...

The safety of nivolumab for the treatment of metastatic melanoma.

O'Reilly, A; Larkin, J (2017-08)

<h4>Introduction</h4>Nivolumab, a human IgG4 monoclonal antibody directed against PD-1, is a checkpoint inhibitor that is licenced in the treatment of metastatic melanoma either as a monotherapy or in combination with ...

Safety of Radium-223+Paclitaxel in Cancer Patients with Bone Metastases: Results from an Open-Label, Multicenter Phase 1b Study

Valicenti, RK; Perets, R; Lopez, J; Danson, S; Joensuu, HT; Peer, A; Harris, SJ; Souza, F; Ploeger, B; Pereira, KMC; Geva, R (ELSEVIER SCIENCE INC, 2017-10-01)

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

Weber, JS; Hodi, FS; Wolchok, JD; Topalian, SL; Schadendorf, D; Larkin, J; Sznol, M; Long, GV; Li, H; Waxman, IM; Jiang, J; Robert, C (2017-03)

Purpose We conducted a retrospective analysis to assess the safety profile of nivolumab monotherapy in patients with advanced melanoma and describe the management of adverse events (AEs) using established safety guidelines. ...

Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.

Coleman, N; Michalarea, V; Alken, S; Rihawi, K; Lopez, RP; Tunariu, N; Petruckevitch, A; Molife, LR; Banerji, U; De Bono, JS; Welsh, L; Saran, F; Lopez, J (2018-08)

BACKGROUND:Primary malignant brain tumours (PMBT) constitute less than 2% of all malignancies and carry a dismal prognosis. Treatment options at relapse are limited. First-in-human solid tumour studies have historically ...

Publications Repository

Publications Repository